Novartis NVS obtains FDA ... disease. Approximately 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis. The approval Vanrafia marks the third ...

Novartis has made kidney disorders ... trying to slow disease progression. The lone therapeutic is tolvaptan, brand name Jynarque, an Otsuka Pharmaceutical drug approved by the FDA in 2018 for ...

Proteinuria is a prominent measure of kidney function, with elevated levels being associated with serious kidney disease. The drug was ... Then the FDA in August handed Novartis’ complement ...